SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Dagenais Gilles R.)
 

Sökning: WFRF:(Dagenais Gilles R.) > Effects of Lipid-Lo...

  • Dagenais, Gilles R.Lava Univ, Quebec Heart & Lung Univ Inst, Quebec City, PQ, Canada (författare)

Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention : An Analysis of the HOPE-3 Trial

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • Wiley,2018
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-372904
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-372904URI
  • https://doi.org/10.1161/JAHA.118.008918DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background It is not clear whether the effects of lipid-lowering or antihypertensive medications are influenced by adherence to healthy lifestyle factors. We assessed the effects of both drug interventions in subgroups by the number of healthy lifestyle factors in participants in the HOPE-3 (Heart Outcomes Prevention Evaluation) trial.Methods and Results In this primary prevention trial, 4 healthy lifestyle factors (nonsmoking status, physical activity, optimal body weight, and healthy diet) were recorded in 12 521 participants who were at intermediate risk of cardiovascular disease (CVD) and were randomized to rosuvastatin, candesartan/hydrochlorothiazide, their combination, or matched placebos. Median follow-up was 5.6 years. The outcome was a composite of CVD events. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression models. Participants with >= 2 healthy lifestyle factors had a lower rate of CVD compared with those with fewer factors (HR: 0.85; 95% CI, 0.73-1.00). Rosuvastatin reduced CVD events in participants with >= 2 healthy lifestyle factors (HR: 0.74; 95% CI, 0.62-0.90) and in participants with <2 factors (HR: 0.79; 95% CI, 0.61-1.01). Consistent results were observed with combination therapy (>= 2 factors: HR: 0.74; 95% CI, 0.57-0.97; <2 factors: HR: 0.61; 95% CI, 0.43-0.88). Candesartan/hydrochlorothiazide tends to reduce CVD only in participants with <2 healthy lifestyle factors (HR: 0.78; 95% CI, 0.61-1.00).Conclusions Healthy lifestyles are associated with lower CVD. Rosuvastatin alone and combined with candesartan/hydrochlorothiazide is beneficial regardless of healthy lifestyle status; however, the benefit of antihypertensive treatment appears to be limited to patients with less healthy lifestyles.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Jung, HyejungMcMaster Univ, Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON, Canada (författare)
  • Lonn, EvaMcMaster Univ, Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON, Canada (författare)
  • Bogaty, Peter M.Lava Univ, Quebec Heart & Lung Univ Inst, Quebec City, PQ, Canada (författare)
  • Dehghan, MahshidMcMaster Univ, Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON, Canada (författare)
  • Held, Claes,1956-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)clahe947 (författare)
  • Avezum, AlvaroUniv Santo Amaro, Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil (författare)
  • Jansky, PetrUniv Hosp Motol, Prague, Czech Republic (författare)
  • Keltai, MatyasSemmelweis Univ, Budapest, Hungary (författare)
  • Leiter, Lawrence A.Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada;Univ Toronto, Dept Med, Toronto, ON, Canada;Univ Toronto, Dept Nutr Sci, Toronto, ON, Canada (författare)
  • Lopez-Jaramillo, PatricioUniv Santander UDES, Med Sch, Res Dept, FOSCAL, Bucaramanga, Colombia (författare)
  • Toff, William D.Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England;NIHR Leicester Biomed Res Ctr, Leicester, Leics, England (författare)
  • Bosch, JackieMcMaster Univ, Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON, Canada (författare)
  • Yusuf, SalimMcMaster Univ, Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON, Canada (författare)
  • Lava Univ, Quebec Heart & Lung Univ Inst, Quebec City, PQ, CanadaMcMaster Univ, Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON, Canada (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of the American Heart Association: Wiley7:152047-9980

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy